Charcot-Marie-Tooth

Living with Charcot-Marie-Tooth Disease

Living with Charcot-Marie-Tooth (CMT) disease means navigating a progressive nerve disorder that affects much more than movement. From early signs like frequent tripping, toe-walking, and trouble with fine motor skills, those living with CMT may experience symptoms such as:

  • Hand/arm weakness (reduced grip strength)

  • Difficulty with mobility (walking, stair climbing)

  • Balance

  • Ankle weakness (foot drop)

  • Muscle fatigue

  • Difficulty breathing

CMT can make everyday tasks feel exhausting. Despite its life-altering impact, CMT remains widely misunderstood and without an FDA-approved treatment. At our company, we appreciate the full reality of living with CMT - and we’re working to develop therapies that truly make a difference.

NMD Pharma’s Treatment Approach: Targeting the Skeletal Muscles in CMT

Currently there is no approved treatment for Charcot-Marie-Tooth disease.

Ignaseclant (formerly known as NMD670) is an experimental oral medicine being tested to help people with CMT. It is a skeletal muscle-targeted therapy that is being investigated for the potential to increase muscle responsiveness to weak nerve signals and enable more consistent muscle function. It is an oral medication taken with a simple glass of water.

Ignaseclant has not been approved by Regulatory Health Authorities and the safety and effectiveness of ignaseclant in SMA, MG or CMT has not been established